These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32704573)

  • 21. Add-on Rehmannia-6-Based Chinese Medicine in Type 2 Diabetes and CKD: A Multicenter Randomized Controlled Trial.
    Chan KW; Kwong ASK; Tan KCB; Lui SL; Chan GCW; Ip TP; Yiu WH; Cowling BJ; Taam Wong V; Lao L; Feng Y; Lai KN; Tang SCW
    Clin J Am Soc Nephrol; 2023 Sep; 18(9):1163-1174. PubMed ID: 37307005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
    Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
    Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
    Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study.
    Otoda T; Sekine A; Uemoto R; Tsuji S; Hara T; Tamaki M; Yuasa T; Tamaki T; Matsuhisa M; Aihara KI
    Diabetes Ther; 2024 Jan; 15(1):127-143. PubMed ID: 37883001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
    Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V
    Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Yoshihara F; Imazu M; Sakuma I; Hiroi Y; Hara H; Okazaki O; Ishiguro C; Izumi C; Noguchi T; Shiraiwa T; Nishioka N; Fujii K; Iwakura K; Tomonaga O; Kobayashi K; Takihata M; Yumoto K; Takase H; Himi T; Shimizu I; Murakami T; Wagatsuma K; Sato K; Hiramatsu T; Akabame S; Hata S; Asakura M; Kawabata T; Omae K; Ito S; Kitakaze M;
    EClinicalMedicine; 2023 Dec; 66():102334. PubMed ID: 38192595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Rovin BH; Barratt J; Heerspink HJL; Alpers CE; Bieler S; Chae DW; Diva UA; Floege J; Gesualdo L; Inrig JK; Kohan DE; Komers R; Kooienga LA; Lafayette R; Maes B; Małecki R; Mercer A; Noronha IL; Oh SW; Peh CA; Praga M; Preciado P; Radhakrishnan J; Rheault MN; Rote WE; Tang SCW; Tesar V; Trachtman H; Trimarchi H; Tumlin JA; Wong MG; Perkovic V;
    Lancet; 2023 Dec; 402(10417):2077-2090. PubMed ID: 37931634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
    Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
    Clin J Am Soc Nephrol; 2021 Dec; 16(12):1824-1832. PubMed ID: 34853062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.
    Persson F; Bain SC; Mosenzon O; Heerspink HJL; Mann JFE; Pratley R; Raz I; Idorn T; Rasmussen S; von Scholten BJ; Rossing P;
    Diabetes Care; 2021 Apr; 44(4):1020-1026. PubMed ID: 33504496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial.
    Mizukoshi T; Kato S; Ando M; Sobajima H; Ohashi N; Naruse T; Saka Y; Shimizu H; Nagata T; Maruyama S
    Nephrology (Carlton); 2018 Nov; 23(11):1023-1030. PubMed ID: 28990729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation Between Serum 25-Hydroxyvitamin D Levels in Albuminuria Progression of Diabetic Kidney Disease and Underlying Mechanisms By Bioinformatics Analysis.
    Huang B; Wen W; Ye S
    Front Endocrinol (Lausanne); 2022; 13():880930. PubMed ID: 35634488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology.
    Waijer SW; Provenzano M; Mulder S; Rossing P; Persson F; Perkovic V; Heerspink HJL
    Diabetes Obes Metab; 2022 Jun; 24(6):983-990. PubMed ID: 35112455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).
    Yoon SA; Han BG; Kim SG; Han SY; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang YH; Shin SH; Cha DR
    Diabetes Obes Metab; 2017 Apr; 19(4):590-598. PubMed ID: 28019072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
    de Zeeuw D; Agarwal R; Amdahl M; Audhya P; Coyne D; Garimella T; Parving HH; Pritchett Y; Remuzzi G; Ritz E; Andress D
    Lancet; 2010 Nov; 376(9752):1543-51. PubMed ID: 21055801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
    JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous Positive Airway Pressure Effect on Albuminuria Progression in Patients with Obstructive Sleep Apnea and Diabetic Kidney Disease: A Randomized Clinical Trial.
    Zamarrón E; Jaureguizar A; García-Sánchez A; Díaz-Cambriles T; Alonso-Fernández A; Lores V; Mediano O; Troncoso-Acevedo F; Cabello-Pelegrín S; Morales-Ruíz E; Ramírez-Prieto MT; Valiente-Díaz MI; Gómez-García T; Casitas R; Martínez-Cerón E; Galera R; Cubillos-Zapata C; García-Río F
    Am J Respir Crit Care Med; 2023 Mar; 207(6):757-767. PubMed ID: 36342964
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.